金融时报
金黄色葡萄球菌
微生物学
耐甲氧西林金黄色葡萄球菌
抗药性
药理学
抗生素
生物
抗菌剂
体内
体外
细菌
生物化学
细菌蛋白
遗传学
生物技术
作者
Manoj Kumar,Tarun Mathur,Tarani Kanta Barman,Tridib Chaira,Ram Kumar,Vattan Joshi,Manisha Pandya,Lalima Sharma,Kunihiko Fujii,Mahadev Bandgar,Balasaheb Jadhav,Ramesh Bambal,Dilip J. Upadhyay,Nobuhisa Masuda,Ashwani Kumar Verma,Pradip K. Bhatnagar
摘要
FtsZ is an essential bacterial protein and an unexplored target for the development of antibacterial drugs. The development of a novel inhibitor targeting FtsZ offers a potential opportunity to combat drug resistance. DS01750413, a new derivative of PC190723, is a novel FtsZ inhibitor with improved in vitro and in vivo activity. The objective of this study was to investigate the efficacy of DS01750413 against Staphylococcus spp., including MRSA, in in vitro and in vivo models.In vitro activities of DS01750413 and standard-of-care antibiotics were evaluated against clinical isolates of Gram-positive pathogens. The in vivo efficacy was evaluated in a murine systemic infection model caused by MRSA.DS01750413 showed potent in vitro activity against MRSA clinical isolates with MIC ranges of 0.5-1 mg/L and also demonstrated concentration-dependent bactericidal killing. In the murine bacteraemia infection model of MRSA, treatment with DS01750413 resulted in prolonged survival of animals compared with placebo-treated animals and exhibited a significant reduction in the bacterial load in liver, spleen, lungs and kidneys.DS01750413 showed encouraging in vitro and in vivo activity against MRSA. As a novel chemical class, DS01750413 has the potential to become clinically viable antibiotics to address the drug resistance problem by its unique novel targeting mechanism of action.
科研通智能强力驱动
Strongly Powered by AbleSci AI